Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Hydroxyurea scored tablets - SIKLOS
Product / population
SIKLOS hydroxyurea 100-mg and 1000-mg scored tablets; sickle cell anemia, age >=2 years
Renal method
CrCl, mL/min, obtained using a 24-hour urine collection
Source revision
November 2023
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
The same 50% renal reduction starts from different adult and pediatric doses
SIKLOS provides separate pediatric and adult starting doses. The DROXIA extract is adult capsule guidance. Applying the adult starting amount to a child would change the regimen even if the percentage reduction were correct.
What to reconcile: Use the exact age/product starting dose, prescribed weight method, measured CrCl instruction and hematology monitoring plan. Related hydroxyurea products remain separate.
DailyMed / Medunik USA · SIKLOS hydroxyurea 100-mg and 1000-mg scored tablets; sickle cell anemia, age >=2 years
Renal method: CrCl, mL/min, obtained using a 24-hour urine collection Source date: November 2023 Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
At CrCl >=60 mL/min, the initial daily dose is 20 mg/kg in pediatric patients and 15 mg/kg in adults. Below 60 or in ESRD, reduce by 50%: 10 mg/kg/day in children and 7.5 mg/kg/day in adults. Obtain CrCl using a 24-hour urine collection. On hemodialysis days, administer after dialysis.
For starting-dose weight, use actual or ideal body weight, whichever is less. Monitor blood counts every two weeks and follow the full escalation, toxicity interruption and recovery instructions. These scored tablets are labeled for sickle cell anemia in adults and children at least two years old; do not substitute the adult DROXIA capsule starting dose for the pediatric SIKLOS dose.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.